GIP/GLP-1 receptor agonist

Tirzepatide

US: FDA-approvedEU: AuthorisedUK: AuthorisedCA: AuthorisedAU: RegisteredCH: AuthorisedBR: RegistadoRS: AuthorisedSG: RegisteredTR: Ruhsatli

Answer

Tirzepatide is authorised or registered in the US, the EU, the UK, Canada, Australia, Switzerland, Brazil, Serbia, Singapore and Turkey: 10 of the 10 registers read. Highest trial phase: Phase 4 (after approval). It has 309 registered trials, 191 of them running. Brand names on the FDA label register: Mounjaro and Zepbound.

RegulatorTrial register10 regulators' registers, read 2026-09-03 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03

Not medical, legal or regulatory advice.

Registered trials309Trial register ClinicalTrials.gov and EU CTIS

Running now191Trial register recruiting, active or enrolling

Results posted47Trial register with results on the register

Stopped early1.6%Trial register all peptides: 10%

309 trials by status

Trial register

Running 191Completed 91Stopped early 5Status unknown 4Other or not stated 18

ClinicalTrials.gov and EU CTIS · read 2026-10-03 · 47 trials have posted results

Trials first submitted per year

Trial register

42017

22018

162019

92020

32021

92022

252023

482024

852025

892026

ClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 2026 is not complete. 19 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).

Status by jurisdiction

World map

CAISNOUSUKEUUACNKRJPMXCHLIRSTRINTHBREGILSAAESGARZAAUNZ

Authorised or registeredNot on the register, or withdrawnNot read yet, or status unknown

Where	Status	Register	Read
United States	FDA-approved	FDA, openfda	2026-10-03
European Union	Authorised	EMA, ema	2026-10-03
United Kingdom	Authorised	MHRA, uk-mhra	2026-10-03
Canada	Authorised	Health Canada, ca-dpd	2026-10-03
Australia	Registered	TGA, au-artg	2026-10-03
Switzerland	Authorised	Swissmedic, ch-swissmedic	2026-10-03
Brazil	Registado	ANVISA, br-anvisa	2026-10-03
Serbia	Authorised	ALIMS, rs-alims	2026-09-03
Singapore	Registered	HSA, sg-hsa	2026-09-03
Turkey	Ruhsatli	TITCK, tr-titck	2026-09-03

An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.

Side effects

Trial register

19 placebo-controlled trials · 6,209 people on Tirzepatide · grey is placebo

Nausea25.6% 8.1%

Diarrhoea21.2% 8.3%

Covid-1915.5% 16%

Constipation13.7% 4.5%

Decreased appetite11.6% 2.9%

ClinicalTrials.gov posted results · read 2026-10-03All side effects

CHANGE ALERTS

Get an email when this changes

One email when the status of Tirzepatide changes on the register. You confirm your address first.

ENFORCEMENT AND OFFICIAL ACTIONS

1 action by named authorities

Enforcement actions, board positions and payer rules that name Tirzepatide, quoted from the source document. These are not approval decisions. This list shows the actions found so far. It is not a complete list: no authority publishes one.

US-OHenforcement

Ohio Board of Pharmacy, 2026-04-16

During the inspection, [redacted] was found to possess multiple vials of the following illegal dangerous drugs, in either a white powder, purple powder, or clear liquid form, intended for injection, which were obtained from an unlicensed, foreign source: c. Tirzepatide 20mg, 6 vials; d. Tirzepatide 50mg, 4 vials;

State of Ohio Board of Pharmacy, Order, Case No. A-2026-0037, Findings of Fact paragraphs 2(c)-2(d) · quoted with the party redacted

REGISTERED TRIALS

Newest 10 of 309 trials

All 309 trials

NCT06861439	GLP-1s to Enhance Lasting Optimal Weight running, but no longer enrolling · register updated 2026-10-02
NCT07065552	Tirzepatide in Obesity-Driven Endometrial Cancer currently recruiting participants · register updated 2026-10-02
NCT07734792	Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial not yet recruiting participants · register updated 2026-10-01
NCT06854614	Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtro running, but no longer enrolling · register updated 2026-09-30
NCT06603571	A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participant completed · register updated 2026-09-29
NCT07527910	A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD currently recruiting participants · register updated 2026-09-29
NCT07845500	A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People W not yet recruiting participants · register updated 2026-09-29
NCT07846865	Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness not yet recruiting participants · register updated 2026-09-29
NCT07847515	Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients not yet recruiting participants · register updated 2026-09-29
NCT06745128	Tirzepatide for Obesity and Meth Use Disorder completed · register updated 2026-09-28

All peptides · Method

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.